You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SIGNAL-BASED ANALYSIS OF CLINICAL MICROBIOLOGY

    SBC: VECNA TECHNOLOGIES, INC            Topic: N/A

    Hospital infections and antimicrobial resistance are scourges of modern society, affecting several million Americans annually and wasting billions of dollars. Timely, accurate data analysis is critical to preventing the spread of infection and resistance. Preliminary results show that treating clinical microbiology data as signals and applying various analytical techniques to them has tremendous p ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  2. TRANSGENIC PRODUCTION OF CD4-IGG2 FOR HIV THERAPY

    SBC: PROGENICS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A major goal of HIV-1 research is the development of nontoxic agents that target novel stages of the viral replicative cycle, such as viral entry. New agents are needed both to combat the growing incidence of HIV-1 strains that are broadly resistant to existing antiretroviral medications and to lessen the considerable toxicities associated with current therapi ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  3. A HYPOXIA ACTIVATED HIF-1 & INHIBITOR FOR CANCER THERAPY

    SBC: PROLX PHARMACEUTICALS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): ProlX Pharmaceuticals, a company focusing on redox targets for development of anti-cancer therapies, has identified PX-478 as a novel hypoxia inducible factor (HIF) inhibitor and hypoxic bystander anti-cancer agent. The initial Phase I SBIR proposal, with aims to synthesize and evaluate novel agents that would be activated within a hypoxic tumor environment, pr ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  4. SPLIT-MAZE DISCOVERY OF ANTIOBESITY DRUGS

    SBC: NOVASITE PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Scanned from the Applicant's Abstract): At Novasite, we have developed a novel system capable of screening compound libraries against thousands of variants of the melanocortin-4 receptor simultaneously, at little additional cost relative to wild type only screening systems. This new technology allows a novel approach to drug discovery, called ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. Cooler for Space-Based Storage of Low-Temperature Cryogens

    SBC: BECK ENGINEERING, INC.            Topic: N/A

    "The Air Force requires the capability to provide cryogenic cooling of electronics, focal plane arrays, and cryogenic fluids for long term (over five year) space missions. In Phase II, we propose to continue developing enabling technology for long-termspace-based low-temperature (

    SBIR Phase II 2002 Department of DefenseAir Force
  6. INEXPENSIVE INTERACTIVE MOLECULAR MODELING SOFTWARE

    SBC: VERACHEM LLC            Topic: N/A

    Today, promising new protein targets for small molecule drugs are being discovered rapid. With increasing frequency, the 3D structures of these proteins are available or can be modeled from known protein structures. Demand is therefor growing for software to support structure-based discovery of protein ligands as candidate drugs. However, existing software leaves enormous room for improvement in a ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  7. IMAGING OF APOPTOSIS

    SBC: MOLECULAR THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to continue development of a novel molecular imaging reporter construct that can report induction of apoptosis in intact cells and animals. Under normal biological conditions a tight balance between proliferation and cell death (apoptosis) is essential. An imbalance in these two opposing processes has been implicated in a va ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  8. NEW DERMAL ANESTHETICS

    SBC: GLSynthesis Inc.            Topic: N/A

    Dermal anesthetics are used to anesthetize the skin of patients for various reasons, ranging from minor cutaneous surgery and needle inserts to skin grafts. The dermal anesthetic market is dominated by a single preparation, called EMLA (AstraZeneca), which consists of a eutectic mixture of lidocaine and prilocaine bases. EMLA?s principal drawback is a long onset time for dermal anesthesia, requiri ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  9. SF/HGF GENE TRANSFER FOR PERIPHERAL ISCHEMIA

    SBC: Angion Biomedica Corp.            Topic: N/A

    Cardiovascular disease is the leading cause of morbidity and mortality in the US, afflicting over 58 million Americans. Angiogenic factors can increase vascularization and improve perfusion in ischemia. Scatter factor/hepatocyte growth factor (SF/HGF) may be superior to other angiogenic factors because of multiple actions on components of the angiogenic cascade and anti-apoptotic properties. Our P ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. TRANSCRIPTIONALLY ACTIVE PCR TO IMPROVE DNA VACCINES

    SBC: GENE THERAPY SYSTEMS, INC.            Topic: N/A

    DESCRIPTION: (Provided by Applicant) DNA vaccines offer an attractive alternative to create effective vaccines that are inexpensive to manufacture, and can be widely distributed. One of the most difficult tasks in developing a DNA vaccine is the identification of the antigen that will stimulate the most effective immune response against the pathogen, particularly when the genome of the infectious ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government